Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Spero Therapeutics clinical trials
The registry lists 22 studies whose lead sponsor is Spero Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 10, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Spero Therapeutics.
- Spero Therapeutics22 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)CompletedNCT06059846Phase 3
- A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary DiseaseCompletedNCT05496374Phase 2
- A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy ParticipantsCompletedNCT06727136Phase 1
- Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal FunctionCompletedNCT04865393Phase 1
- A Study to Compare Two Bioanalytical Assays for TebipenemCompletedNCT05856747Phase 1
- A Study to Assess the Intrapulmonary Pharmacokinetics (PK) of SPR719 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Oral Administration of Multiple Doses of SPR720 in Healthy Volunteers.CompletedNCT05955586Phase 1
- A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy ParticipantsCompletedNCT05966688Phase 1
- Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)CompletedNCT03788967Phase 3
- Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary DiseaseTerminatedNCT04553406Phase 2
- Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy VolunteersCompletedNCT04868292Phase 1
- Effect of Tebipenem on Normal Human Intestinal MicrobiotaCompletedNCT04376554Phase 1
- Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking VolunteersCompletedNCT04710407Phase 1
- Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal FunctionCompletedNCT04178577Phase 1
- Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male SubjectsCompletedNCT04625855Phase 1
- Study to Examine the Effect of Antacid and Omeprazole on the Single-Dose Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult SubjectsCompletedNCT04368585Phase 1
- Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult SubjectsCompletedNCT04421885Phase 1
- A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy SubjectsCompletedNCT04238195Phase 1
- A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy VolunteersCompletedNCT03792308Phase 1
- A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy VolunteersCompletedNCT03796910Phase 1
- Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994CompletedNCT03395249Phase 1
- Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741CompletedNCT03376529Phase 1
- A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy VolunteersCompletedNCT03022175Phase 1